Thomas Lothar, Franck Susanne, Messinger Maren, Linssen Jo, Thomé Marcus, Thomas Christian
Department of Laboratory Medicine, Krankenhaus Nordwest, Frankfurt am Main, Germany.
Clin Chem Lab Med. 2005;43(11):1193-202. doi: 10.1515/CCLM.2005.207.
The aims of this study were to diagnose iron-restricted erythropoiesis (functional iron deficiency) in patients with classic iron deficiency (ID), anemia of chronic disease (ACD) and the combined state of ID/ACD with the use of two hematological methods for the measurement of reticulocyte hemoglobinization. In comparison, the biochemical markers of iron status were determined. We studied 474 anemic patients admitted to hospital with a broad spectrum of diseases. We measured indicators of reticulocyte hemoglobinization. CHr was determined on an Advia 120 hematology analyzer. A Sysmex XE-2100 hematology analyzer was used to determine RET-Y, the forward scatter of fluorescence-labeled reticulocytes, which can also be expressed as the reticulocyte hemoglobin equivalent (RET-H(e)), as well as RBC-Y, the forward scatter of fluorescence-labeled erythrocytes, which can be expressed as the erythrocyte hemoglobin equivalent. Ferritin, soluble transferrin receptor (sTfR) and the sTfR/log ferritin ratio (sTfR-F index) were used as biochemical markers. The comparison of RET-Y with CHr demonstrated an excellent curvilinear relationship between the two parameters. The normal reference range for Ret-Y was 1630-1860 arbitrary units (AU); mathematical transformation to RET-H(e) gave a range of 28.2-35.7 pg. Correlations of biochemical iron markers with RET-H(e) were as weak as with CHr in patients with ACD and acute phase response. In a diagnostic plot to identify iron status, RET-H(e) could replace CHr without any loss of sensitivity or specificity. Patient mismatch analysis between RET-H(e) and CHr in the diagnostic plot demonstrated agreement for 449 of 474 patients (94.4%). Patient specific anemia mismatches were 2.9-6.2%. According to our results, the indicators of reticulocyte hemoglobinization, RET-H(e) and CHr, measure the same phenomenon. RET-H(e) is as valuable as CHr for the diagnosis of iron-restricted erythropoiesis. The combination of RET-H(e) and the sTfR-F index in a diagnostic plot offers an attractive tool for the evaluation of iron status and identification of the progression of ID.
本研究的目的是通过两种测量网织红细胞血红蛋白化的血液学方法,诊断经典缺铁(ID)、慢性病贫血(ACD)以及ID/ACD合并状态患者的铁限制红细胞生成(功能性缺铁)。作为比较,还测定了铁状态的生化标志物。我们研究了474例因多种疾病入院的贫血患者。我们测量了网织红细胞血红蛋白化指标。使用Advia 120血液分析仪测定CHr。使用Sysmex XE - 2100血液分析仪测定RET - Y,即荧光标记网织红细胞的前向散射,也可表示为网织红细胞血红蛋白当量(RET - H(e)),以及RBC - Y,即荧光标记红细胞的前向散射,可表示为红细胞血红蛋白当量。铁蛋白、可溶性转铁蛋白受体(sTfR)以及sTfR/对数铁蛋白比值(sTfR - F指数)用作生化标志物。RET - Y与CHr的比较显示这两个参数之间存在良好的曲线关系。Ret - Y的正常参考范围为1630 - 1860任意单位(AU);经数学转换为RET - H(e)后范围为28.2 - 35.7 pg。在ACD和急性期反应患者中,生化铁标志物与RET - H(e)的相关性与与CHr的相关性一样弱。在用于识别铁状态的诊断图中,RET - H(e)可替代CHr,且不损失任何敏感性或特异性。诊断图中RET - H(e)与CHr之间的患者不匹配分析显示,474例患者中有449例一致(94.4%)。患者特异性贫血不匹配率为2.9% - 6.2%。根据我们的结果,网织红细胞血红蛋白化指标RET - H(e)和CHr测量的是同一现象。RET - H(e)在诊断铁限制红细胞生成方面与CHr一样有价值。在诊断图中将RET - H(e)与sTfR - F指数结合,为评估铁状态和识别ID的进展提供了一个有吸引力的工具。